United Therapeutics (NASDAQ:UTHR) Announces Quarterly Earnings Results

United Therapeutics (NASDAQ:UTHRGet Rating) posted its quarterly earnings data on Wednesday. The biotechnology company reported $5.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.65 by $1.38, MarketWatch Earnings reports. United Therapeutics had a return on equity of 12.80% and a net margin of 28.23%. The company had revenue of $461.90 million for the quarter, compared to the consensus estimate of $420.02 million. During the same period in the previous year, the business earned $0.61 EPS. United Therapeutics’s revenue for the quarter was up 21.8% compared to the same quarter last year.

United Therapeutics stock opened at $186.36 on Thursday. The firm has a market capitalization of $8.41 billion, a P/E ratio of 18.58, a P/E/G ratio of 6.82 and a beta of 0.64. The company has a 50-day simple moving average of $180.20 and a 200-day simple moving average of $192.63. United Therapeutics has a one year low of $158.38 and a one year high of $218.38. The company has a debt-to-equity ratio of 0.20, a quick ratio of 7.30 and a current ratio of 7.61.

Several research firms recently issued reports on UTHR. StockNews.com raised United Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Friday, April 1st. HC Wainwright reissued a “buy” rating on shares of United Therapeutics in a research report on Friday, February 25th. Wedbush reissued a “buy” rating and set a $236.00 price target (down from $276.00) on shares of United Therapeutics in a research report on Sunday, February 27th. JPMorgan Chase & Co. reduced their price target on shares of United Therapeutics from $230.00 to $223.00 and set an “overweight” rating for the company in a report on Tuesday, April 19th. Finally, BTIG Research began coverage on shares of United Therapeutics in a research report on Friday, February 11th. They set a “neutral” rating for the company. Two equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, United Therapeutics currently has an average rating of “Buy” and an average price target of $215.00.

In related news, EVP Paul A. Mahon sold 6,000 shares of the company’s stock in a transaction dated Thursday, March 3rd. The shares were sold at an average price of $174.12, for a total value of $1,044,720.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders sold 30,000 shares of company stock valued at $5,600,460 in the last ninety days. Corporate insiders own 12.10% of the company’s stock.

A number of hedge funds have recently bought and sold shares of the stock. Thrivent Financial for Lutherans lifted its holdings in United Therapeutics by 1.2% in the fourth quarter. Thrivent Financial for Lutherans now owns 11,875 shares of the biotechnology company’s stock worth $2,566,000 after purchasing an additional 141 shares during the period. Advisors Asset Management Inc. lifted its holdings in United Therapeutics by 13.2% in the 4th quarter. Advisors Asset Management Inc. now owns 3,209 shares of the biotechnology company’s stock valued at $693,000 after acquiring an additional 375 shares during the last quarter. Metropolitan Life Insurance Co NY lifted its holdings in United Therapeutics by 10.1% in the 4th quarter. Metropolitan Life Insurance Co NY now owns 8,040 shares of the biotechnology company’s stock valued at $1,737,000 after acquiring an additional 736 shares during the last quarter. Forum Financial Management LP acquired a new stake in United Therapeutics in the 4th quarter valued at about $226,000. Finally, JustInvest LLC lifted its holdings in United Therapeutics by 55.0% in the 4th quarter. JustInvest LLC now owns 3,167 shares of the biotechnology company’s stock valued at $684,000 after acquiring an additional 1,124 shares during the last quarter. 94.68% of the stock is owned by institutional investors and hedge funds.

About United Therapeutics (Get Rating)

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

Featured Articles

Earnings History for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.